Overview

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

Personalized Education (powered by ACHL AdaptED®)

Time to Complete

1.25 hr(s).

Release Date

December 22, 2023

Expires On

December 22, 2024

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEd® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results.

Hear from our expert faculty about the advantages of the ACHL AdaptED® learning experience:

This activity is intended for hematologists, oncologists, and the multidisciplinary care team who care for/manage patients with R/R MM.

Multiple myeloma (MM) remains an incurable malignancy. Even with aggressive initial therapy, most patients experience relapse, and the 5-year survival rate is just 56%. The recent boon of novel therapies, including targeted bispecific antibodies offers new opportunities to enhance efficacy for patients in the relapsed/refractory setting. However, these new therapies have also made the treatment selection process substantially more complex for providers. This education aims to empower healthcare teams to navigate emerging therapies effectively.

Upon completion of this activity, learners will be able to:

• Review the rationale for targeting BCMA in the treatment of R/R MM and the mechanisms of action of BCMA-directed agents
• Discuss the latest clinical data evaluating BCMA-targeted bispecific antibodies for the treatment of patients with R/R MM
• Incorporate recent clinical evidence into selecting BCMA-targeted bispecific antibodies for an individual patient with heavily treated R/R MM
• Develop strategies to assess individual patient risk for treatment-specific adverse events based on clinical factors when sequencing BCMA-targeted therapies in heavily treated patients
• Outline the mechanisms of action and available clinical evidence with novel bispecific antibodies for R/R MM

BCMA rationale and MOA of BCMA bispecifics
MOA: Novel bispecifics
Safety and efficacy
Adverse events
Treatment selection and sequencing

Co-provided by the Cleveland Clinic Center for Continuing Education and the Academy for Continued Healthcare Learning (ACHL).

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

Faiz Anwer, MD, FACP
Associate Professor of Medicine, Multiple Myeloma Program
Hematology, Oncology, Stem Cell Transplantation
Director, Inpatient Lymphoma Myeloma Service
Taussig Cancer Center
Cleveland Clinic
Cleveland, OH

Surbhi Sidana, MD

Assistant Professor of Medicine

Stanford Medicine

Palo Alto, CA

In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education and ACHL require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Faiz Anwer, MD, FACP

Sources of Funding for Research: Bristol Myers Squibb

Consulting Agreements: Bristol Myers Squibb

Speakers' Bureau: Bristol Myers Squibb

Surbhi Sidana, MD

Consulting Agreements: Bristol Myers Squibb, Janssen, Kite Pharma, Magenta Therapeutics, Oncopeptides, Sanofi, Takeda

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Novel combination approaches under investigation.

The Cleveland Clinic Center for Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The Cleveland Clinic Center for Continuing Education requires the speaker to disclose that a product is not labeled for the use under discussion.

To receive credit, learners are required to view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Cleveland Clinic Center for Continuing Education designates this application-based activity for a maximum of 1.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Universal Activity Number List:
Pharmacist UAN: JA0000192-0000-23-330-H01-P
Release Date: December 22, 2023 / Expiration Date: December 22, 2024

Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 1.25 ANCC contact hours.

Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Laurie Novoryta
lnovoryta@achlcme.org

Overview

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Meeting Schedule

Provider Information

Supporter Information

Hardware and Software Requirement

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities